Taysha Gene Therapies, Inc. TSHA
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -27.27%
- 1 year
- -19.35%
- Open
- 4.30
- Prev close
- 4.13
- Mkt cap
- 1.30B
- Vol
- 2.01M
- Avg vol
- 3.54M
- EPS
- -0.41
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.95
- High
- 4.20
- Forward P/E
- -8.65
- Beta
- 1.31
- Short ratio
- 10.79
- Inst. own
- 94.28%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 4.82
- 200-d avg
- 5.32
- 1y target
- 13.00
5D chart
Signals (79)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:00 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:55 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:50 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:50 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:40 PM | 6 days ago |
| RSI: Overbought | Oct 27, 3:40 PM | 6 days ago |
| RSI: Overbought | Oct 27, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 6 days ago |
| RSI: Overbought | Oct 27, 10:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 1 week ago |
| MACD: Sell Signal | Oct 26, 3:20 PM | 1 week ago |
| MACD: Buy Signal | Oct 26, 3:15 PM | 1 week ago |
| SMA: Bullish | Oct 26, 2:05 PM | 1 week ago |
| MACD: Sell Signal | Oct 26, 1:05 PM | 1 week ago |
| SMA: Bearish | Oct 26, 12:40 PM | 1 week ago |
| SMA: Bearish | Oct 26, 12:40 PM | 1 week ago |
| SMA: Bullish | Oct 26, 12:15 PM | 1 week ago |
| SMA: Bearish | Oct 26, 11:30 AM | 1 week ago |
| SMA: Bearish | Oct 26, 10:30 AM | 1 week ago |
News
2 weeks ago defenseworld.net
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week Low – Time to Sell?
Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $3.55 and last traded at $3.58, with a…
3 weeks ago defenseworld.net
Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head Analysis
Taysha Gene Therapies (NASDAQ: TSHA - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the…
1 month ago globenewswire.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus…
-
1 month ago benzinga.com
Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meeting
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic…
1 month ago globenewswire.com
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus…
-
1 month ago benzinga.com
Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform rating.
1 month ago seekingalpha.com
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and disciplined execution for TSHA-102 in Rett syndrome. TSHA's $455.4M cash runway extends into H2…
1 month ago marketbeat.com
These 3 Risky Stocks Could Be Sitting on 100% Upside
With industrials, energy, and tech stocks undergirding an S&P 500 that is hovering near all-time highs, investors looking for high-upside companies may be resigned to more speculative plays. While…
1 month ago globenewswire.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus…
2 months ago defenseworld.net
Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA
Bank of America Corp DE raised its stake in Taysha Gene Therapies, Inc. (NASDAQ: TSHA) by 45.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange…
2 months ago seekingalpha.com
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential…
-
2 months ago benzinga.com
Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 44.44 percent decrease over losses…
2 months ago globenewswire.com
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA…
2 months ago globenewswire.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus…
3 months ago globenewswire.com
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus…
3 months ago globenewswire.com
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla.
-
3 months ago benzinga.com
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13
Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.
-
4 months ago benzinga.com
Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target
Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and maintains $11 price target.
4 months ago seekingalpha.com
Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential
Taysha Gene Therapies (TSHA) remains a "Buy," driven by strong TSHA-102 data in Rett Syndrome and pivotal trial progress. TSHA-102 achieved 100% response rate at 12 months in Part A, surpassing the…
4 months ago benzinga.com
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Canaccord cut Strategy's target, Barclays upgraded Watts Water, Rosenblatt boosted Comcast, Goldman…
-
4 months ago benzinga.com
Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $12 to $15.
4 months ago globenewswire.com
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity
4 months ago benzinga.com
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session
U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release and offer to acquire Advanced Medical Solutions.
4 months ago benzinga.com
Why Micron Technology Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Shares of Micron Technology Inc (NASDAQ: MU) surged in pre-market trading after reporting strong Q3 results and issuing strong guidance. Autozi Internet Technology, Focus Universal, SAGTEC GLOBAL,…
4 months ago globenewswire.com
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus…
4 months ago benzinga.com
9 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines…
-
4 months ago benzinga.com
Taysha Gene Therapies Commences $200M Common Stock Offering
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic…
4 months ago globenewswire.com
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus…
-
4 months ago benzinga.com
BMO Capital Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $14
BMO Capital analyst Keith Tapper maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $10 to $14.
-
4 months ago benzinga.com
B of A Securities Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10
B of A Securities analyst Tazeen Ahmad maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $9 to $10.
-
4 months ago benzinga.com
Citizens Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $11
Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and raises the price target from $8 to $11.
4 months ago seekingalpha.com
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript
-
4 months ago benzinga.com
Taysha Gene Therapies Completes Dosing In REVEAL Prival Study Of 17 Females In Developmental Plateau Population Of Rett Syndrome
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic…
4 months ago globenewswire.com
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
DALLAS, June 22, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus…
4 months ago benzinga.com
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.
-
6 months ago benzinga.com
Taysha Gene Therapies Q1 EPS $(0.12) Misses $(0.10) Estimate
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 50 percent decrease over losses of…
-
6 months ago benzinga.com
Taysha Gene Therapies To Reveal New Preclinical Data Supporting Construct Design Of TSHA-102 For Rett Syndrome At The ASGCT 2026 Annual Meeting
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic…
-
7 months ago benzinga.com
Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Raises Price Target to $17
Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $14 to $17.
-
7 months ago benzinga.com
Taysha Gene Therapies Q4 EPS $(0.12) Misses $(0.10) Estimate, Sales $5.485M Beat $1.889M Estimate.
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 23.71 percent. This is a 71.43 percent decrease over…
-
7 months ago benzinga.com
Earnings Scheduled For March 19, 2026
Earnings Scheduled For March 19, 2026
-
8 months ago benzinga.com
Needham Reiterates Buy on Taysha Gene Therapies, Maintains $10 Price Target
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $10 price target.
-
10 months ago benzinga.com
Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $12 Price Target
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $12 price target.
-
10 months ago benzinga.com
Taysha Gene Therapies Advances TSHA‑102 Rett Syndrome Program; First Patient Dosed In REVEAL Pivotal Trial, FDA Alignment On ASPIRE Safety Data For Broad BLA, Dosing Completion Expected Q2 2026 With Longer‑Term Data Update In H1 2026
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across multiple sitesReached written alignment with FDA on inclusion…
-
12 months ago benzinga.com
Citizens Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $8
Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and raises the price target from $6 to $8.
-
12 months ago benzinga.com
Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $12 Price Target
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $12 price target.
-
12 months ago benzinga.com
Taysha Gene Therapies Q3 EPS $(0.09), Inline. Revenue $0. Cash And Equivalents $299.94M.
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.10) per share from the…
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
-
1 year ago benzinga.com
Raymond James Initiates Coverage On Taysha Gene Therapies with Strong Buy Rating, Announces Price Target of $13
Raymond James analyst Christopher Raymond initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Strong Buy rating and announces Price Target of $13.